Quantcast
Last updated on April 18, 2014 at 14:44 EDT

Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination

July 8, 2011

AMSTERDAM, July 7, 2011 /PRNewswire/ –

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field
of human gene therapy, announced today that it has filed a request for
re-examination of the Marketing Authorisation Application for Glybera(R)with
the European Medicines Agency. Glybera is a gene therapy for the genetic
disorder lipoprotein lipase deficiency. The Company expects that the
re-examination of the dossier will be completed by the end of 2011.

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies.
The company’s lead product Glybera(R), a gene therapy for lipoprotein lipase
deficiency (LPLD), is currently under review by the European Medicines
Agency (EMA). If approved, Glybera will be the first gene therapy product to
be marketed in Europe. AMT also has a product pipeline of several gene
therapy products in development for hemophilia B, Duchenne muscular
dystrophy, acute intermittent porphyria, Parkinson’s disease and
SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the
delivery vehicle of choice for therapeutic genes, the company has been able
to design and validate probably the world’s first stable and scalable AAV
manufacturing platform. This proprietary platform can be applied to a large
number of rare (orphan) diseases caused by one faulty gene and allows AMT to
pursue its strategy of focusing on this sector of the industry. AMT was
founded in 1998 and is based in Amsterdam. Further information can be found
at http://www.amtbiopharma.com.

Certain statements in this press release are “forward-looking
statements” including those that refer to management’s plans and
expectations for future operations, prospects and financial condition. Words
such as “strategy,”"expects,”"plans,”"anticipates,”"believes,”"will
,”"continues,”"estimates,”"intends,”"projects,”"goals,”"targets” and other
words of similar meaning are intended to identify such forward-looking
statements. Such statements are based on the current expectations of the
management of AMT only. Undue reliance should not be placed on these
statements because, by their nature, they are subject to known and unknown
risks and can be affected by factors that are beyond the control of AMT.
Actual results could differ materially from current expectations due to a
number of factors and uncertainties affecting AMT’s business. AMT expressly
disclaims any intent or obligation to update any forward-looking statements
herein except as required by law.

SOURCE Amsterdam Molecular Therapeutics B.V


Source: newswire